• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket

    11/22/22 6:22:00 AM ET
    $ACHV
    $BFRI
    $COSM
    $CYCN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHV alert in real time by email

    Gainers

    • ObsEva SA (NASDAQ:OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million.
    • Secoo Holding Limited (NASDAQ:SECO) shares rose 24% to $0.3450 in pre-market trading.
    • Cosmos Holdings Inc. (NASDAQ:COSM) rose 17% to $0.2050 in pre-market trading after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.
    • Gaotu Techedu Inc. (NYSE:GOTU) shares jumped 13.2% to $1.20 in pre-market trading after the company posted a narrower quarterly loss.
    • Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) rose 12.5% to $0.63 in pre-market trading after gaining around 8% on Monday.
    • Nexalin Technology, Inc. (NASDAQ:NXL) rose 12.2% to $2.30 in pre-market trading after surging around 14% on Monday.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) rose 8.9% to $0.74 in pre-market trading. First Wave BioPharma reported a private placement.
    • Biofrontera Inc. (NASDAQ:BFRI) rose 8.8% to $1.05 in pre-market trading. Biofrontera will launch Phase 3 clinical study evaluating Ameluz-PDT for the treatment of actinic keratosis on the extremities, neck and trunk.
    • Achieve Life Sciences, Inc. (NASDAQ:ACHV) rose 8% to $2.70 in pre-market trading. Achieve Life Sciences recently reported a private placement of $18.9 million.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) rose 7.9% to $0.1080 in pre-market trading after declining over 10% on Monday.
    • EUDA Health Holdings Limited (NASDAQ:EUDA) rose 7.1% to $4.05 in pre-market trading after dipping 15% on Monday.


    Don’t forget to check out our premarket coverage here .


    Losers

    • Gamida Cell Ltd. (NASDAQ:GMDA) fell 18% to $1.46 in pre-market trading after the company issued a regulatory update on Omidubicel. The company said it received extension of Omidubicel PDUFA Date from Jan. 30, 2023 to May 1, 2023 as the FDA issued information request.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) shares fell 14.7% to $0.4004 in pre-market trading after jumping 10% on Monday.
    • Tantech Holdings Ltd (NASDAQ:TANH) shares fell 13.5% to $1.80 in pre-market trading. Tantech Holdings recently announced a 1-for-24 common share consolidation.
    • Zoom Video Communications, Inc. (NASDAQ:ZM) fell 9.2% to $72.81 in pre-market trading after the company reported better-than-expected results, but issued weak guidance.
    • Drive Shack Inc. (NYSE:DS) shares fell 9.1% to $0.4002 in pre-market trading after jumping 23% on Monday. Drive Shack recently reported Q3 EPS and sales results were higher year over year.
    • Venus Concept Inc. (NASDAQ:VERO) shares fell 9% to $0.1820 in pre-market trading after gaining over 10% on Monday. The company recently posted downbeat quarterly sales.
    • Siyata Mobile Inc. (NASDAQ:SYTA) fell 8.8% to $0.1771 in pre-market trading after jumping 26% on Monday.
    • Canoo Inc. (NASDAQ:GOEV) fell 6.9% to $1.08 in pre-market trading. The company recently posted a narrower-than-expected quarterly loss.
    • Meta Materials Inc. (NASDAQ:MMAT) fell 6.4% to $2.02 in pre-market trading after jumping 30% on Monday. Meta Materials recently posted a Q3 loss of $0.07 per share.
    • Eqonex Limited (NASDAQ:EQOS) fell 6.3% to $0.1965 in pre-market trading after dipping around 24% on Monday.
    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV
    $BFRI
    $COSM
    $CYCN

    CompanyDatePrice TargetRatingAnalyst
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Zoom Communications Inc.
    $ZM
    1/12/2026$106.00Neutral → Buy
    Citigroup
    Zoom Communications Inc.
    $ZM
    12/17/2025$105.00Buy
    BTIG Research
    Achieve Life Sciences Inc.
    $ACHV
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    Zoom Communications Inc.
    $ZM
    10/21/2025$85.00Equal-Weight
    Morgan Stanley
    Zoom Communications Inc.
    $ZM
    10/20/2025$85.00Neutral
    UBS
    Achieve Life Sciences Inc.
    $ACHV
    8/21/2025$12.00Buy
    H.C. Wainwright
    Zoom Communications Inc.
    $ZM
    6/6/2025Underweight
    KeyBanc Capital Markets
    More analyst ratings

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

    SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referenci

    3/17/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Pindrop Zoom Integration Embeds Real-Time Deepfake Detection and Identity Verification in Zoom Contact Center

    ATLANTA, March 12, 2026 (GLOBE NEWSWIRE) -- Pindrop, the innovator behind the Real Human + Right Human™ Platform for the AI era, today announced an expanded integration with Zoom to bring real-time deepfake detection for Zoom Contact Center. The integration embeds Pindrop's AI-driven voice authentication, synthetic media detection and fraud risk intelligence directly within Zoom's CX platform—bringing identity trust into the flow of everyday customer engagement. According to Pindrop's Inside the 2025 AI Fraud Spike report, AI-driven fraud surged 1,210% in 2025, significantly outpacing traditional fraud growth, with synthetic audio emerging as a growing threat vector across contact centers

    3/12/26 9:00:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

    CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative. Following this purchase, Cosmos Health's total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum. Greg Siokas, CEO of Cosmos Health, stated: "We continue to view select digital assets as an attractive asset class with strong upside potential. Our growing position in Bitcoin and Ethereum reflects a disciplined treasury strategy design

    3/11/26 1:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    SEC Filings

    View All

    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    3/9/26 9:20:28 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Gaotu Techedu Inc.

    6-K - Gaotu Techedu Inc. (0001768259) (Filer)

    3/5/26 6:01:17 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    SEC Form S-8 filed by Zoom Communications Inc.

    S-8 - Zoom Communications, Inc. (0001585521) (Filer)

    3/2/26 1:04:38 PM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoom Communications upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Zoom Communications from Peer Perform to Outperform and set a new price target of $115.00

    2/5/26 6:52:31 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Zoom Communications upgraded by Citigroup with a new price target

    Citigroup upgraded Zoom Communications from Neutral to Buy and set a new price target of $106.00

    1/12/26 7:53:13 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    BTIG Research resumed coverage on Zoom Communications with a new price target

    BTIG Research resumed coverage of Zoom Communications with a rating of Buy and set a new price target of $105.00

    12/17/25 9:30:41 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chen Xiangdong claimed ownership of 800,000 units of Class A ordinary shares, claimed ownership of 73,305,288 units of Class B ordinary shares and claimed ownership of 7,514,529 units of ADSs (SEC Form 3)

    3 - Gaotu Techedu Inc. (0001768259) (Issuer)

    3/12/26 6:15:38 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    New insider Shen Nan claimed ownership of 460,091 units of ADSs (SEC Form 3)

    3 - Gaotu Techedu Inc. (0001768259) (Issuer)

    3/12/26 6:11:51 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    SEC Form 3 filed by new insider Sun Hao (Felix)

    3 - Gaotu Techedu Inc. (0001768259) (Issuer)

    3/12/26 6:08:04 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    $ACHV
    $BFRI
    $COSM
    $CYCN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

    SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve's legal strategy, corporate governance, compliance, and risk management. "Erik's extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential laun

    10/20/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Financials

    Live finance-specific insights

    View All

    Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

    SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referenci

    3/17/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gaotu Techedu Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 5, 2026 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE:GOTU) ("Gaotu" or the "Company"), a leading technology-driven education company in China focused on enabling lifelong learning through AI-powered solutions, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights[1]Net revenues were RMB1,685.3 million, increased by 21.4% from RMB1,388.6 million in the same period of 2024.Gross billings[2] were RMB2,573.7 million, increased by 19.1% from RMB2,160.2 million in the same period of 2024.Loss from operations was RMB118.0 million, compared with loss from operations of RMB149.3 million in the same per

    3/5/26 1:13:00 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gaotu Techedu Inc.

    SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)

    11/27/24 6:02:40 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care